These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24853733)

  • 1. Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group.
    Hutchison C; Kwong A; Ray S; Struble K; Swan T; Miller V
    Clin Pharmacol Ther; 2014 Aug; 96(2):162-5. PubMed ID: 24853733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV versus HIV drug discovery: Déjà vu all over again?
    Watkins WJ; Desai MC
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2281-7. PubMed ID: 23489621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The design of drugs for HIV and HCV.
    De Clercq E
    Nat Rev Drug Discov; 2007 Dec; 6(12):1001-18. PubMed ID: 18049474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic approaches for hepatitis C.
    Au JS; Pockros PJ
    Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel treatments for hepatitis C.
    Webster DP; Klenerman P; Collier J; Jeffery KJ
    Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
    Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B.
    Rai R; Deval J
    Antiviral Res; 2011 May; 90(2):93-101. PubMed ID: 21295075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of new oral hepatitis C antiviral drugs.
    Vispo E; Barreiro P; Soriano V
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):5-16. PubMed ID: 23094639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients.
    Medrano J; Resino S; Vispo E; Madejón A; Labarga P; Tuma P; Martín-Carbonero L; Barreiro P; Rodriguez-Novoa S; Jiménez-Nacher I; Soriano V
    J Viral Hepat; 2011 May; 18(5):325-30. PubMed ID: 20456635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
    Kwong AD; Najera I; Bechtel J; Bowden S; Fitzgibbon J; Harrington P; Kempf D; Kieffer TL; Koletzki D; Kukolj G; Lim S; Pilot-Matias T; Lin K; Mani N; Mo H; O'Rear J; Otto M; Parkin N; Pawlotsky JM; Petropoulos C; Picchio G; Ralston R; Reeves JD; Schooley RT; Seiwert S; Standring D; Stuyver L; Sullivan J; Miller V; ; ; ;
    Gastroenterology; 2011 Mar; 140(3):755-60. PubMed ID: 21255574
    [No Abstract]   [Full Text] [Related]  

  • 16. New therapeutic prospects in HCV treatment.
    Almasio PL; Ingrassia D; Vergara B; Filosto S
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890
    [No Abstract]   [Full Text] [Related]  

  • 17. New pharmacotherapy for hepatitis C.
    Assis DN; Lim JK
    Clin Pharmacol Ther; 2012 Sep; 92(3):294-305. PubMed ID: 22850602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.